590 reports of this reaction
1.9% of all EVEROLIMUS TABLETS reports
#11 most reported adverse reaction
PYREXIA is the #11 most commonly reported adverse reaction for EVEROLIMUS TABLETS, manufactured by Amneal Pharmaceuticals NY LLC. There are 590 FDA adverse event reports linking EVEROLIMUS TABLETS to PYREXIA. This represents approximately 1.9% of all 31,530 adverse event reports for this drug.
Patients taking EVEROLIMUS TABLETS who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for EVEROLIMUS TABLETS, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for EVEROLIMUS TABLETS:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 590 FDA reports for EVEROLIMUS TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 1.9% of all adverse event reports for EVEROLIMUS TABLETS, making it a notable side effect.
If you experience pyrexia while taking EVEROLIMUS TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.